Attached files
| file | filename |
|---|---|
| EX-99.1 - REPROS THERAPEUTICS INC. | v205835_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Filed Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report
(Date
of earliest event reported): December 16, 2010
Repros
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-15281
|
76-0233274
|
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
2408
Timberloch Place, Suite B-7
The
Woodlands, Texas 77380
(Address
of principal
executive
offices
and
zip code)
|
||
|
(281)
719-3400
(Registrant’s
telephone number, including area code)
|
||
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
8.01 Other Events.
On
December 16, 2010, Repros Therapeutics Inc. (the “Company”) issued a press
release titled “Repros®
Therapeutics Prepares to Commence Dosing in Second Cohort in Low Dose
Proellex®
Study.” A copy of such press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated December 16,
2010
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
|
Repros
Therapeutics Inc.
|
||
|
Date: December
16, 2010
|
By:
|
/s/ Joseph S. Podolski | |
| Joseph S. Podolski | |||
| President and Chief Executive Officer | |||
EXHIBIT
INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
Press
Release dated December 16, 2010
|